UPDATE: 4D Molecular Therapeutics Q4 EPS $0.43 Beats $(0.53) Estimate, Sales $85.090M Beat $32.245M Estimate

4D Molecular Therapeutics (NASDAQ: FDMT) reported Q4 earnings of $0.43 per share, exceeding the analyst estimate of $(0.53) by 181.13%, and marking a 147.78% improvement from a loss of $(0.90) per share in the same quarter last year. The company also achieved quarterly sales of $85.090 million, surpassing the $32.245 million estimate by 163.89%, and showing a significant increase from $1,000 in sales during the same period last year.